Back to results
US 2014/0234257 A1Published application
Oncolytic Viruses and Methods for Treating Neoplastic Disorders
AssigneeThe Governors of the University of Alberta
InventorsDavid H. Evans, Don B. Gammon
Life of this patent
Estimating the term…
Abstract
The disclosure provides mutant ribonucleotide reductase strains of poxviruses including for example vaccinia viruses. The disclosure also provides methods and for the use of these mutant ribonucleotide reductase strains of vaccinia viruses in oncolytic virotherapy.
Claims18
-43. (canceled)
A composition comprising:
- an Orthopoxvirus comprising a gene encoding a modified R2 protein comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:
- 1,
- wherein the modified R2 protein expressed by the Orthopoxvirus comprises a deletion of at least a part of R1 binding domain (R1BD);
- and
- wherein the Orthopoxvirus does not express a wild type R2 protein.
2 more elements
A method for inducing lysis of a neoplastic disorder cell, the method comprising:
- contacting said cell with an effective amount of an Othropoxvirus comprising a gene encoding a modified R2 protein comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:
- 1,
- wherein the modified R2 protein expressed by the Orthopoxvirus comprises a substitution of a tyrosine residue, wherein the substituted tyrosine residue corresponds to position 300 of SEQ ID NO:
- 1, or
- wherein the modified R2 protein expressed by the Orthopoxvirus comprises a deletion of at least a part of R1 binding domain (R1BD);
- and
- wherein said contacting is effective to induce lysis in the neoplastic disorder cell.
4 more elements
A method for treating a neoplastic disorder, the method comprising:
- administering an effective amount of an Othropoxvirus comprising a gene encoding a modified R2 protein comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:
- 1,
- wherein the modified R2 protein expressed by the Orthopoxvirus comprises a substitution of a tyrosine residue, wherein the substituted tyrosine residue corresponds to position 300 of SEQ ID NO:
- 1, or
- wherein the modified R2 protein expressed by the Orthopoxvirus comprises a deletion of at least a part of R1 binding domain (R1BD).
2 more elements
Dependencies are inferred from the claim text.